Restricted accessResearch articleFirst published online 2022-04
Photobiomodulation Modulates Interleukin-10 and Interferon Gamma Production by Mononuclear Cells from Healthy Donors and Persons with Multiple Sclerosis
Photobiomodulation (PBM) therapy was previously shown to reduce the clinical severity of disease and modulated pro- and anti-inflammatory cytokines in an animal model of multiple sclerosis (MS).
Objective:
Previous observations were extended to determine the effect of PBM therapy on peripheral blood mononuclear cells and CD4+ T cells isolated from persons with MS (PwMS) and healthy donors.
Methods:
Using an in vitro cell culture system, isolated cells were activated and treated with red or near-infrared light wavelengths to determine the effect of PBM on the production of interferon gamma and interleukin-10 (IL-10).
Results:
PBM modulated cytokine production in MS subjects and healthy donors in a dose- and wavelength-dependent manner, with MS subjects and healthy donors responding differently to administered light. In addition, disease severity affected the response of immune cells, for instance, 670 nm increased IL-10 production associated with increased disease severity.
Conclusions:
The data show that PBM therapy has the potential to modulate pro- and anti-inflammatory cytokines in PwMS over the course of disease. Further experiments applying PBM treatment directly on patients should be carried out with extreme caution to avoid severe imbalance in the immune response.
Get full access to this article
View all access options for this article.
References
1.
DuttaR, TrappBD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol, 2011; 93:1–12.
2.
MS Overview. Multiple Sclerosis Association of America, 2018. Available at: https://mymsaa.org/ms-informationoverview/process-symptoms (Last accessed December2021).
3.
DuffySS, LeesJG, Moalem-TaylorG. The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult Scler Int, 2014; 2014:285245.
4.
RiedhammerC, WeissertR. Antigen presentation, autoantigens, and immune regulation in multiple sclerosis and other autoimmune diseases. Front Immunol, 2015; 6:322.
5.
DamalK, StokerE, FoleyJF. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biol Targets Therapy, 2013; 7:247–258.
6.
RommerPS, MiloR, HanMH, et al.Immunological aspects of approved MS therapeutics. Front Immunol, 2019; 10:1564.
7.
ChungH, DaiT, SharmaSK, HuangYY, CarrollJD, HamblinMR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng, 2012; 40:516–533.
8.
YuZ, LiuN, ZhaoJ, et al.Near infrared radiation rescues mitochondrial dysfunction in cortical neurons after oxygen-glucose deprivation. Metab Brain Dis, 2015; 30:491–496.
9.
XuanW, VatanseverF, HuangL, et al.Transcranial low-level laser therapy improves neurological performance in traumatic brain injury in mice: effect of treatment repetition regimen. PLoS One, 2013; 8:e53454.
10.
OronA, OronU, ChenJ, et al.Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. Stroke, 2006; 37:2620–2624.
11.
MogesH, VasconcelosOM, CampbellWW, et al.Light therapy and supplementary Riboflavin in the SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis (FALS). Lasers Surg Med, 2009; 41:52–59.
12.
ByrnesKR, WaynantRW, IlevIK, et al.Light promotes regeneration and functional recovery and alters the immune response after spinal cord injury. Lasers Surg Med, 2005; 36:171–185.
13.
NaeserMA, SaltmarcheA, KrengelMH, HamblinMR, KnightJA. Improved cognitive function after transcranial, light-emitting diode treatments in chronic, traumatic brain injury: two case reports. Photomed Laser Surg, 2011; 29:351–358.
14.
LamplY, ZivinJA, FisherM, et al.Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke, 2007; 38:1843–1849.
15.
DetaboadaL, IlicS, Leichliter-MarthaS, OronU, OronA, StreeterJ. Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke. Lasers Surg Med, 2006; 38:70–73.
16.
PurushothumanS, JohnstoneDM, NandasenaC, MitrofanisJ, StoneJ. Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex—evidence from two transgenic mouse models. Alzheimers Res Therapy, 2014; 6:2.
17.
GrilloSL, DuggettNA, EnnaceurA, ChazotPL. Non-invasive infra-red therapy (1072nm) reduces beta-amyloid protein levels in the brain of an Alzheimer's disease mouse model, TASTPM. J Photochem Photobiol B Biol, 2013; 123:13–22.
18.
TrimmerPA, SchwartzKM, BorlandMK, De TaboadaL, StreeterJ, OronU. Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy. Mol Neurodegener, 2009; 4:26.
19.
PastoreD, GrecoM, PassarellaS. Specific helium-neon laser sensitivity of the purified cytochrome c oxidase. Int J Radiat Biol, 2000; 76:863–870.
20.
GrecoM, GuidaG, PerlinoE, MarraE, QuagliarielloE. Increase in RNA and protein synthesis by mitochondria irradiated with helium-neon laser. Biochem Biophys Res Commun, 1989; 163:1428–1434.
21.
KaruT.Primary and secondary mechanisms of action of visible to near-IR radiation on cells. J Photochem Photobiol B Biol, 1999; 49:1–17.
22.
PastoreD, GrecoM, PetragalloVA, PassarellaS. Increase in <—H+/e- ratio of the cytochrome c oxidase reaction in mitochondria irradiated with helium-neon laser. Biochem Mol Biol Int, 1994; 34:817–826.
23.
HamblinMR.Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys, 2017; 4:337–361.
24.
MuiliKA, GopalakrishnanS, MeyerSL, EellsJT, LyonsJA. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by photobiomodulation induced by 670nm light. PLoS One, 2012; 7:e30655.
25.
HoholMJ, OravEJ, WeinerHL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology, 1995; 45:251–255.
26.
HoholMJ, OravEJ, WeinerHL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler, 1999; 5:349–354.
27.
LiuG, MuiliKA, AgasheVV, LyonsJA. Unique B cell responses in B cell-dependent and B cell-independent EAE. Autoimmunity, 2012; 45:199–209.
28.
KaruTI, PyatibratLV, KolyakovSF, AfanasyevaNI. Absorption measurements of cell monolayers relevant to mechanisms of laser phototherapy: reduction or oxidation of cytochrome c oxidase under laser radiation at 632.8nm. Photomed Laser Surg, 2008; 26:593–599.
29.
ChenAC, AranyPR, HuangYY, et al.Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS One, 2011; 6:e22453.
SharmaSK, KharkwalGB, SajoM, et al.Dose response effects of 810nm laser light on mouse primary cortical neurons. Lasers Surg Med, 2011; 43:851–859.
32.
ChenAC, HuangYY, SharmaSK, HamblinMR. Effects of 810-nm laser on murine bone-marrow-derived dendritic cells. Photomed Laser Surg, 2011; 29:383–389.
33.
Wong-RileyMT, LiangHL, EellsJT, et al.Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem, 2005; 280:4761–4771.
34.
BrosnanCF, CannellaB, BattistiniL, RaineCS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology, 1995; 45:S16–S21.
35.
OlssonT.Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol, 1992; 40:211–218.
36.
RennoT, LinJY, PiccirilloC, AntelJ, OwensT. Cytokine production by cells in cerebrospinal fluid during experimental allergic encephalomyelitis in SJL/J mice. J Neuroimmunol, 1994; 49:1–7.
37.
RennoT, TaupinV, BourbonniereL, et al.Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci, 1998; 12:376–389.
38.
RennoT, KrakowskiM, PiccirilloC, LinJY, OwensT. TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. J Immunol, 1995; 154:944–953.
39.
PanitchHS, HirschRL, SchindlerJ, JohnsonKP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology, 1987; 37:1097–1102.
40.
SkurkovichS, BoikoA, BeliaevaI, et al.Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult Scler, 2001; 7:277–284.
41.
FerberIA, BrockeS, Taylor-EdwardsC, et al.Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol, 1996; 156:5–7.
WillenborgDO, FordhamS, BernardCC, CowdenWB, RamshawIA. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol, 1996; 157:3223–3227.
44.
BilliauA, HeremansH, VandekerckhoveF, et al.Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol, 1988; 140:1506–1510.
45.
DuongTT, St LouisJ, GilbertJJ, FinkelmanFD, StrejanGH. Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse. J Neuroimmunol, 1992; 36:105–115.
ChuCQ, WittmerS, DaltonDK. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med, 2000; 192:123–128.
48.
VoorthuisJA, UitdehaagBM, De GrootCJ, GoedePH, van der MeidePH, DijkstraCD. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats. Clin Exp Immunol, 1990; 81:183–188.
49.
HeremansH, DillenC, GroenenM, MartensE, BilliauA. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. Eur J Immunol, 1996; 26:2393–2398.
50.
DuongTT, FinkelmanFD, SinghB, StrejanGH. Effect of anti-interferon-gamma monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains. J Neuroimmunol, 1994; 53:101–107.
51.
SabatinoJJJr., ShiresJ, AltmanJD, FordML, EvavoldBD.Loss of IFN-gamma enables the expansion of autoreactive CD4+ T cells to induce experimental autoimmune encephalomyelitis by a nonencephalitogenic myelin variant antigen. J Immunol, 2008; 180:4451–4457.
52.
XiaoBG, MaCG, XuLY, LinkH, LuCZ. IL-12/IFN-gamma/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. Mol Immunol, 2008; 45:1191–1196.
53.
FurlanR, BrambillaE, RuffiniF, et al.Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol, 2001; 167:1821–1829.
54.
SamoilovaEB, HortonJL, ChenY. Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery. Cell Immunol, 1998; 188:118–124.
55.
BettelliE, DasMP, HowardED, WeinerHL, SobelRA, KuchrooVK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol, 1998; 161:3299–3306.
56.
BrodSA, NelsonLD, KhanM, WolinskyJS. Increased in vitro induced CD4+ and CD8+ T cell IFN-gamma and CD4+ T cell IL-10 production in stable relapsing multiple sclerosis. Int J Neurosci, 1997; 90:187–202.
57.
Rodriguez-Sainz MdelC, Sanchez-RamonS, de AndresC, Rodriguez-MahouM, Munoz-FernandezMA. Th1/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis. Eur Cytok Netw, 2002; 13:110–114.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
